Clinical Trial Update: Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2") [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating intravesical instillations of BotuGel and slow-release RTGel-based Botox formulations for idiopathic overactive bladder wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• BotuGel
• RTGel-Based Botox Formulations

Snippet

Sponsor: UroGen Pharma Ltd. | Conditions: Overactive Bladder | Phase 1, Phase 2 | Status: WITHDRAWN